[Pharmacokinetic and clinical studies on latamoxef in the field of obstetrics and gynecology].
Latamoxef (LMOX) 1 g was administered twice daily for 5 days to patients undergoing operation for myoma uteri and the time course of tissue concentrations of the drug and the prophylactic effect of the treatment on postoperative infection were studied. 1. Area under concentration-time curve (AUC) of LMOX was the highest in the perimetrium (45.3%), followed by the cervix uteri (39.2%), endometrium (35.9%), oviduct (35.1%), myometrium (29.5%), and ovary (24.4%). 2. Cmax was the highest in oviduct (46.9 micrograms/g), followed by Cmax's in perimetrium (44.2 micrograms/g), cervix uteri (35.8 micrograms/g), myometrium (26.9 micrograms/g), endometrium (25.6 micrograms/g), and ovary (24.3 micrograms/g). 3. Serum half-lives were T1/2(alpha) = 0.27 hour and T1/2(beta) = 1.81 hours. 4. Prophylactic efficacy against postoperative infections was 94.3%, and febrile morbidity was 5.7%. The preoperative and postoperative laboratory tests did not show appreciable changes, no adverse reaction was observed. In the present study, LMOX showed good transfer into gynecological tissues, suggesting its very high usefulness in the treatment of infection and in the postoperative management.
Shindo
K
K
Department of Obstetrics and Gynecology, Koritsu Kesennuma Sogo Hospital.
Oikawa
N
N
Chida
S
S
Tsuburaya
T
T
Sato
M
M
D000328:Adult; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000601:surgery*; D008875:Middle Aged; D009070:Moxalactam / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011292:Premedication; D013530:Surgical Wound Infection / Q000517:prevention & control*; D014594:Uterine Neoplasms / Q000601:surgery*
D009070:Moxalactam